Trial Profile
Phase II trial of Avastin [bevacizumab] plus bortezomib for patients with recurrent malignant glioma
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 May 2021
Price :
$35
*
At a glance
- Drugs Bevacizumab (Primary) ; Bortezomib (Primary)
- Indications Glioma
- Focus Therapeutic Use
- 03 Feb 2014 Status changed from active, no longer recruiting to completed, as per ClinicalTrials.gov record.
- 28 May 2013 Planned number of patients changed from 61 to 56 as reproted by ClinicalTrials.gov.
- 28 May 2013 Planned end date changed from 1 Aug 2012 to 1 Aug 2014 as reproted by ClinicalTrials.gov.